(19)
(11) EP 4 161 581 A1

(12)

(43) Date of publication:
12.04.2023 Bulletin 2023/15

(21) Application number: 21740294.0

(22) Date of filing: 03.06.2021
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
C07K 16/30(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6811; A61K 47/6851; A61P 35/00; A61K 47/6849; A61K 47/6879; A61K 47/6889; C07K 2317/92; C07K 2317/622; C07K 16/3092; C07K 16/2863; C07K 2317/31; C07K 2317/24; C07K 2317/55; C07K 2317/64; C07K 2317/34; C07K 2317/33; C07K 2317/77
(86) International application number:
PCT/US2021/035600
(87) International publication number:
WO 2021/247798 (09.12.2021 Gazette 2021/49)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 03.06.2020 US 202063034296 P

(71) Applicant: Merck Patent GmbH
64293 Darmstadt (DE)

(72) Inventors:
  • KNUEHL, Christine
    64293 Darmstadt (DE)
  • TOLEIKIS, Lars
    64293 Darmstadt (DE)
  • AMENDT, Christiane
    64293 Darmstadt (DE)
  • DOERNER, Achim
    64293 Darmstadt (DE)
  • LI, Xiaofan
    South San Francisco, CA 94080 (US)
  • STAFFORD, Ryan
    South San Francisco, CA 94080 (US)
  • HENNINGSEN, Robert
    South San Francisco, CA 94080 (US)
  • ZHOU, Sihong
    South San Francisco, CA 94080 (US)
  • YAM, Alice
    South San Francisco, CA 94080 (US)

   


(54) BISPECIFIC ANTIBODY-DRUG CONJUGATES TARGETING EGFR AND MUC1 AND USES THEREOF